Showing results (51-60 of 108) with videos related to

Sort By:
Pageof 11
Cell Reports. Medicine|January 14, 2025
Single-molecule systems for the detection and monitoring of plasma-circulating nucleosomes and oncoproteins in diffuse midline gliomaNir Erez, Noa Furth, Vadim Fedyuk, et al.
Oncotarget|September 2, 2016
Characterizing and targeting PDGFRA alterations in pediatric high-grade gliomaCarl Koschmann, Daniel Zamler, Alan MacKay, et al.
Neuro-Oncology|February 27, 2019
Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendationsZachary Miklja, Amy Pasternak, Stefanie Stallard, et al.
Biorxiv : the Preprint Server for Biology|September 10, 2024
H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibitionYupei Guo, Zian Li, Leslie A Parsels, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2020
Electronic DNA Analysis of CSF Cell-free Tumor DNA to Quantify Multi-gene Molecular Response in Pediatric High-grade GliomaAmy K Bruzek, Karthik Ravi, Ashwath Muruganand, et al.
Neuro-Oncology Advances|November 16, 2022
Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapySharon L Gardner, Rohinton S Tarapore, Jeffrey Allen, et al.
Cancer & Metabolism|April 9, 2024
Purine salvage promotes treatment resistance in H3K27M-mutant diffuse midline gliomaErik R Peterson, Peter Sajjakulnukit, Andrew J Scott, et al.
Neuro-Oncology|April 10, 2025
H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibitionYupei Guo, Zian Li, Leslie A Parsels, et al.
Research Square|October 4, 2023
Adaptive rewiring of purine metabolism promotes treatment resistance in H3K27M-mutant diffuse midline gliomaErik R Peterson, Peter Sajjakulnukit, Andrew J Scott, et al.
Molecular Cancer Therapeutics|July 14, 2026
H3K27M enhances basal ATM signaling but is not required for radiosensitization of diffuse midline glioma via ATM inhibition with AZD1390Erik R Peterson, Leslie A Parsels, Zian Li, et al.
Pageof 11